Celldex Therapeutics, Inc.
CLDX
$41.95
-$0.66-1.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 22.00K | 15.00K | 121.00K | -- | 730.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.00K | 15.00K | 121.00K | -- | 730.00K |
| Cost of Revenue | 67.54M | 73.00M | 75.33M | 62.93M | 54.20M |
| Gross Profit | -67.52M | -72.99M | -75.21M | -62.93M | -53.47M |
| SG&A Expenses | 13.10M | 11.45M | 11.94M | 10.69M | 10.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.65M | 84.45M | 87.27M | 73.62M | 64.59M |
| Operating Income | -80.62M | -84.44M | -87.15M | -73.62M | -63.86M |
| Income Before Tax | -73.50M | -78.69M | -81.32M | -67.04M | -56.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -73.50M | -78.69M | -81.32M | -67.04M | -56.60M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.50M | -78.69M | -81.32M | -67.04M | -56.60M |
| EBIT | -80.62M | -84.44M | -87.15M | -73.62M | -63.86M |
| EBITDA | -79.72M | -83.58M | -86.34M | -72.79M | -62.98M |
| EPS Basic | -0.94 | -1.18 | -1.22 | -1.01 | -0.85 |
| Normalized Basic EPS | -0.59 | -0.74 | -0.76 | -0.63 | -0.53 |
| EPS Diluted | -0.94 | -1.18 | -1.22 | -1.01 | -0.85 |
| Normalized Diluted EPS | -0.59 | -0.74 | -0.76 | -0.63 | -0.53 |
| Average Basic Shares Outstanding | 77.84M | 66.57M | 66.49M | 66.42M | 66.39M |
| Average Diluted Shares Outstanding | 77.84M | 66.57M | 66.49M | 66.42M | 66.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |